The best science demands the best people—and at BioAgilytix’s Boston lab, there’s no shortage of skilled and dedicated scientists. Get to know one of our expert flow cytometry scientists and longtime Boston team member, Benjamin Lamothe.
Bruton’s tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling and is a proven therapeutic target for autoimmune diseases. In recent months, BTK inhibitors are also being deployed in the fight against COVID-19.
As COVID-19 lockdowns begin to lift, the question is: where do we go from here? BioAgilytix is in a highly unique position to help both biopharma & companies with testing to keep their work on track: whether that means progressing clinical trials or reopening their businesses and offices safely.
We are privileged to be working in collaboration with representatives of the Prion Alliance at the Broad Institute, on the development of a Prion ELISA. Why would we include this story in our blog? Well, it is because two aspects of this project are noteworthy; read on.
Services
Platforms